Evidence map›Paper›PMID 29114605›Full record

ArticleAdvances in radiation oncology

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.

Chelsea C Pinnix, Therese Y Andraos, Bouthaina Dabaja, Sarah Milgrom, Grace Smith, Dai Chihara, Andrea Ng, Luis E Fayad, Yasuhiro Oki, Sattva Neelapu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chelsea C PinnixDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Therese Y AndraosDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Bouthaina DabajaDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Sarah MilgromDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Grace SmithDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Dai ChiharaDepartment of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Andrea NgDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.
Luis E FayadDepartment of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Yasuhiro OkiDepartment of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Sattva NeelapuDepartment of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Jason WestinDepartment of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
M Alma RodriguezDepartment of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Loretta J NastoupilDepartment of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe population of patients aged 80 years or older who are diagnosed with diffuse large B-cell lymphoma (DLBCL) continues to increase, but an optimal treatment strategy has not been established. We sought to examine the influence of consolidative radiation therapy (RT) on outcome and toxicity among the very elderly diagnosed with stage I-IV DLBCL. METHODS AND MATERIALS: We evaluated 131 patients treated at a single institution between 2002 and 2014 who were eligible for RT after successful treatment with chemotherapy.

resultsThe median age was 83 years (range, 80-96). Advanced-stage disease was present in 61.8% of patients. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone was administered to 80% of patients (n = 108), and 23.7% of patients received consolidative RT. Among early-stage (ES) patients treated with 3 to 4 cycles of chemotherapy and RT (n = 12) versus 6 to 8 cycles of chemotherapy alone (n = 17), there were no statistically significant differences in 3-year disease-free, progression-free, or overall survival rates. The 3 year disease-free survival was 91.7% versus 88.2% among patients treated with combined modality therapy versus chemotherapy alone (

conclusionsAmong patients aged 80 years or older who have with ES DLBCL, 3 to 4 cycles of chemotherapy followed by RT is at least equivalent in efficacy to chemotherapy alone and is associated with lower levels of toxicity, which suggests that it may be a better choice for therapy when trying to balance treatment efficacy and tolerability.

Identifiers

PMID29114605
PMCPMC5605286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.